Overview

A Study of JNJ-64304500 in Participants With Alopecia Areata

Status:
Withdrawn
Trial end date:
2022-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical response of 22 weeks of study intervention with JNJ-64304500, compared with placebo, in participants with moderate to severe alopecia areata (AA).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC